) launched the latest reagent kits for its industry leading
benchtop sequencer MiSeq. This underlines the company's emphasis
on continued innovation to enhance performance and value of its
As per management, the newest reagent kits offer unique MiSeq
system enhancements in order to provide highest data quality to
clinicians. Moreover, the enhancements will expand research
applications in the field of cancer, genetic disease,
agriculture, microbiology and forensics. This appears to be a
significant upside for Illumina as these markets represent
lucrative revenue opportunities.
Additionally, the affirmative response from the very first
customer of Illumina's new MiSeq kits - Institute for Human
Genetics, Medical University of Graz in Austria is encouraging.
We believe that positive feedback from beta users should support
uptake of the new kits.
We are upbeat about the launch of the new reagent kits as it is
likely to bolster revenues from MiSeq systems for Illumina. This
should expand the installed base for the system and thereby boost
the sequencing consumables business for the company.
Illumina is well positioned to maintain its leadership in the
expanding high-end genetic research market. We believe the
company will continue to be a key player in driving the
development of research tools into clinical/diagnostic
applications. With more emphasis on the new line of products and
global distribution platform, Illumina expects to sustain the
growth momentum going forward.
Based on the recent impressive positive earnings surprise and the
bullish estimate revision trend, the stock carries a Zacks Rank
#2 (Buy). Other stocks that warrant a look are
Gilead Sciences Inc.
). These stocks carry Zacks Rank #1 (Strong Buy).
AFFYMETRIX INC (AFFX): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
GILEAD SCIENCES (GILD): Free Stock Analysis
ILLUMINA INC (ILMN): Free Stock Analysis
To read this article on Zacks.com click here.